Psoriasis Treatment

 Recent study determined the cost-effectiveness of apremilast for the treatment of active psoriasis for adult patients who failed to respond to or are intoler-ant to disease-modifying antirheumatic drugs in UK. A Markov state-transition cohort model was adapted to the UK setting to compare costs and quality-adjusted life-years (QALYs) from 2 treatment sequences: apremilast, adali-mumab, etanercept, infliximab, and best supportive care (BSC) versus adalimumab, etanercept, infliximab, and BSC. The analysis time horizon was 40 years using a 28-day cycle length. The perspective of the UK National Health Service (NHS) was chosen. Treatment efficacy data (based on American College of Rheumatology [ACR] 20 criteria and Psoriasis Area and Severity Index [PASI] 50/75/90 response rates) were derived  from  a  network  meta-analysis  including  13  clinical  trials.  Resource  use  and unit costs were derived from Italian standard source...

 In 2021 Study, Thirty-two Psoriatic Arthritis patients classified according to the CASPAR criteria and attending the Rheumatology Unit of the University of Padua Medical Center were enrolled in a two-year prospective, observational study. In accordance with the ASAS/EULAR recommendations on the management of these patients, those studied were prescribed biological agents [etanercept (n = 21), adalimumab (n = 6), infliximab (n = 5)]. Plasma lipids, inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), vessel endothelium growth factor (VEGF), osteoprotegerin (OPG), and TNF-α, as well as Disease Activity Score 28 calculated with CRP (DAS 28-CRP) were evaluated at baseline and after two years of treatment. Bilateral carotid B-mode ultrasound measurements [the mean-intima media thickness (mean-IMT), the mean maximum-IMT (M-Max)] of each carotid artery segment (common, bulb, and internal carotid artery) and the post-occlusion flow-mediated dilation (FMD) of ...